<![CDATA[EPCORE FL-1 Regimen Shows Value Across R/R Follicular Lymphoma Subgroups]]>

ConferencepositiveepcoritamabEPCORE FL-1Positive

AI Analysis

Summary

Epcoritamab/R² combination (EPCORE FL-1 regimen) demonstrated clinical benefit across relapsed/refractory follicular lymphoma subgroups in data presented at EHA by Dr. Benoit Tessoulin.

Clinical Trial Data

Outcome Details

epcoritamab/R² combination demonstrated benefit across relapsed/refractory follicular lymphoma subgroups

Importance:5/10

Sentiment:

0.60

follicular lymphomarelapsed/refractoryEHA conferencecombination therapy

Related Companies

$GMAB

Read the original article

Published by Cancer Network on July 1, 2026 8:00 PM

Read Original